Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
- DOI
- 10.1136/jitc-2021-003388
- Published
- 2021 Nov
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2021-003388,
title = {Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.},
author = {Conlon K and Watson DC and Waldmann TA and Valentin A and Bergamaschi C and Felber BK and Peer CJ and Figg WD and Potter EL and Roederer M and McNeel DG and Thompson JA and Gupta S and Leidner R and Wang-Gillam A and Parikh NS and Long D and Kurtulus S and Ho Lee L and Chowdhury NR and Bender F and Pavlakis GN},
year = {2021},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2021-003388},
url = {https://doi.org/10.1136/jitc-2021-003388}
}RIS
TY - JOUR TI - Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. AU - Conlon K AU - Watson DC AU - Waldmann TA AU - Valentin A AU - Bergamaschi C AU - Felber BK AU - Peer CJ AU - Figg WD AU - Potter EL AU - Roederer M AU - McNeel DG AU - Thompson JA AU - Gupta S AU - Leidner R AU - Wang-Gillam A AU - Parikh NS AU - Long D AU - Kurtulus S AU - Ho Lee L AU - Chowdhury NR AU - Bender F AU - Pavlakis GN PY - 2021 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2021-003388 UR - https://doi.org/10.1136/jitc-2021-003388 ER -
APA
K, C., DC, W., TA, W., A, V., C, B., BK, F., CJ, P., WD, F., EL, P., M, R., DG, M., JA, T., S, G., R, L., A, W., NS, P., D, L., S, K., L, H. L., NR, C., F, B., & GN, P. (2021). Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2021-003388
Source records
- pubmed · retrieved 2026-09-26T10:33:24.585Z